Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
29
30
Next >
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
October 14, 2023
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...
Via
Talk Markets
2 Surefire Stocks That Could Make You Richer
October 11, 2023
It won't happen overnight, but with these stocks, a little patience is all you need.
Via
The Motley Fool
(SNY) - Analyzing Sanofi's Short Interest
October 09, 2023
Via
Benzinga
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
October 09, 2023
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.
Via
Investor's Business Daily
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
October 06, 2023
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).
Via
Benzinga
What's Going On With Mirati Therapeutics Stock?
October 06, 2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday.
Via
Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
October 04, 2023
Benzinga
Via
Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
October 04, 2023
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.
Via
Investor's Business Daily
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
October 04, 2023
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and
Via
Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
October 04, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Via
Benzinga
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Why Shares of Kymera Therapeutics Jumped on Tuesday
October 03, 2023
The company had a big bounce after hitting a 52-week low the day before.
Via
The Motley Fool
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
October 03, 2023
Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb
Via
Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
October 03, 2023
AstraZeneca Plc (NASDAQ: AZN) has
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
September 30, 2023
If the biotech does split its stock, it will be a first for the company.
Via
The Motley Fool
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
September 27, 2023
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
September 27, 2023
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE
Via
Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 26, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
September 25, 2023
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV
Via
Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
September 21, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 21, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.
Via
Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
September 21, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
September 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
September 21, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories
September 20, 2023
Benzinga
Via
Benzinga
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray
September 20, 2023
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.